Treatment with recombinant human erythropoietin (rHuEPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life.

Treatment with recombinant human erythropoietin (rHuEPO) in dialysis patients has been shown to be highly effective in terms of correcting anaemia and improving quality of life.

However, it can be treated with human recombinant erythropoietin.

All trials compared human recombinant erythropoietin (EPO), for different durations (8, 12 and 52 weeks), versus placebo.

However, this conclusion is based on randomized controlled trials with a high risk of bias, and relies on trials assessing human recombinant erythropoietin (EPO).

The present invention relates, in general, to a method of purifying recombinant human erythropoietin (EPO).

In particular, methods for treating chemotherapy-induced anemia in subjects refractory to treatment with recombinant human erythropoietin are encompassed herein.

This update Cochrane review six randomized trials (537 participants), all of which investigated recombinant human erythropoietin.

Each horse had been given recombinant human erythropoietin (rhEPO; 4,000 IU) at least twice within the preceding 2 to 4 months.

Furthermore, recombinant human erythropoietin did not increase hemoglobin levels and improve quality of life in HIV-infected patients with anemia.